TMCnet News

Alchemia Names Jenni Pilcher as CFO [Professional Services Close - Up]
[August 28, 2014]

Alchemia Names Jenni Pilcher as CFO [Professional Services Close - Up]


(Professional Services Close - Up Via Acquire Media NewsEdge) Alchemia Limited reported the appointment of Jenni Pilcher as its Chief Financial Officer (CFO).

According to a release from the Company, Pilcher brings financial leadership experience to Alchemia. She is currently the CFO of Mesoblast, where she has been part of the executive team for the past seven years, and she also serves as Company Secretary. Jenni's appointment is effective on September 1.



As a member of Mesoblast's executive team during a period of rapid growth for the company, Jenni built the finance group and partnered with the CEO to successfully execute four capital raises totaling more than $230m with Australian, US and UK investors. She was also a key executive in the successful completion of several transactions including a major out-licensing transaction, a company acquisition, a product acquisition, and a contract manufacturing partnership. In 2012, Jenni added the role of Company Secretary to her CFO responsibilities.

"After an extensive search, we are very pleased to add such a high caliber financial leader to our team," commented Thomas Liquard, Chief Executive Officer of Alchemia. "Jenni has an outstanding track record in the biotech industry and her executive maturity and experience will be of great benefit to Alchemia as we enter what is a critical phase in the company's development with the impending results of our pivotal trial for HA-Irinotecan in metastatic colorectal cancer (mCRC)." Prior to joining Mesoblast, Jenni spent six years with ASX 200 company Spotless Group, progressing through a variety of financial roles, and also worked within the finance teams at Cadbury Schweppes plc and international pharmaceutical group Medeva plc, both based in the United Kingdom.


Alchemia is a drug discovery and development company marketing FDA approved fondaparinux, an injectible antithrombotic in the US, as well as other major markets via partner Dr. Reddy's Laboratories.

((Comments on this story may be sent to [email protected])) (c) 2014 ProQuest Information and Learning Company; All Rights Reserved.

[ Back To TMCnet.com's Homepage ]